Fluoguide AS Cash Flow Conversion Efficiency
Fluoguide AS cash flow conversion efficiency. Based on the latest financial reports, Fluoguide AS (FLUO) has a cash flow conversion efficiency ratio of 4.485x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-10.97 Million ≈ $-1.18 Million USD) by net assets (Skr-2.44 Million ≈ $-263.12K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Fluoguide AS (2018–2024)
Cash flow conversion efficiency of Fluoguide AS from 2018 to 2024. This chart illustrates how Fluoguide AS's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Fluoguide AS stock price today for real-time trading data and today's change.
Fluoguide AS Cash Flow Conversion Ratio Explained
Fluoguide AS cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Fluoguide AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Fluoguide AS ranked by their cash flow conversion efficiency. Also see how much is Fluoguide AS worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Yojee Ltd
AU:YOJ
|
-0.167x |
|
Seoul Auction Co. Ltd
KQ:063170
|
0.048x |
|
Globaltec Formation Bhd
KLSE:5220
|
0.061x |
|
ATrack Technology
TWO:6465
|
0.175x |
|
Pliant Therapeutics Inc
NASDAQ:PLRX
|
-0.087x |
|
Averbuch Formica Center Ltd
TA:AVER
|
0.047x |
|
Santova Ltd
JSE:SNV
|
0.078x |
|
Accelerate Property Fund Ltd
JSE:APF
|
0.025x |
Annual Cash Flow Conversion Efficiency for Fluoguide AS (2018–2024)
The table below shows the annual cash flow conversion efficiency of Fluoguide AS from 2018 to 2024. Review FLUO cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr23.07 Million ≈ $2.48 Million |
Skr-29.15 Million ≈ $-3.14 Million |
-1.264x | +49.46% |
| 2023-12-31 | Skr12.72 Million ≈ $1.37 Million |
Skr-31.81 Million ≈ $-3.42 Million |
-2.501x | -112.36% |
| 2022-12-31 | Skr31.97 Million ≈ $3.44 Million |
Skr-37.65 Million ≈ $-4.05 Million |
-1.178x | -202.57% |
| 2021-12-31 | Skr38.70 Million ≈ $4.16 Million |
Skr-15.06 Million ≈ $-1.62 Million |
-0.389x | +80.60% |
| 2020-12-31 | Skr4.41 Million ≈ $474.69K |
Skr-8.85 Million ≈ $-952.08K |
-2.006x | +13.68% |
| 2019-12-31 | Skr4.54 Million ≈ $488.79K |
Skr-10.55 Million ≈ $-1.14 Million |
-2.323x | -1390.74% |
| 2018-12-31 | Skr7.00K ≈ $753.31 |
Skr-1.09K ≈ $-117.41 |
-0.156x | -- |
About Fluoguide AS
FluoGuide A/S, a clinical stage biotechnology company, focuses on developing drugs for surgical outcomes by making cancer fluorescent in Denmark. Its lead product candidate is FG001, which is in Phase IIa and IIb for the treatment of high-grade glioma; Phase II clinical trial for the treatment of lung cancer, and head and neck cancer. The company has a collaboration agreement with ZEISS Medical T… Read more